DOCS Q3 CY2026 deep dive: AI-driven product expansion meets margin compression

Doximity reported Q3 CY2026 revenue of $174.5M, beating estimates by 2%, with adjusted EPS in line. Adjusted EBITDA exceeded expectations by 9.1%, but operating margin fell to 25.2% from 37.8% YoY. The company raised full-year revenue guidance to $680.5M and maintained EBITDA guidance at $321M. AI product adoption surged, with 16 of the top 20 pharma companies using AI Search. New health system clients and partnerships were added, driving growth.

Original reporting
Published Nov 9, 2026, 12:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DOCS Q3 CY2026 deep dive: AI-driven product expansion meets margin compression — source image
Decision brief

The 30-second read

$DOCSNeutralMed
01

Why it matters

Earnings beat on top line but margin compression may temper short‑term price moves; guidance lift is modest.

02

Market read

The release provides fresh data for traders focused on health‑tech and AI‑enabled healthcare platforms.

03

What to watch

The partnership with UpToDate and entry into paid search could unlock new revenue streams beyond the current guidance horizon.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Doximity reported Q3 2026 results, highlighting AI product adoption, new hospital clients, and a partnership with UpToDate.

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

Q3 2026 earnings release with revenue beat, margin compression and updated full-year guidance.

Expected impact

likely pressure as investors weigh margin compression against revenue beat and modest guidance raise

Evidence & confidence

The mix of a revenue beat and margin decline creates uncertainty, prompting short‑term downside risk despite a slight guidance uplift.

Market effects

AI‑driven health‑tech firms may see heightened scrutiny on margin sustainability despite usage growth.

U.S. healthcare‑tech sector could experience modest volatility as peers react to Doximity's margin trends.

Limited to U.S. listed health‑tech equities; no broader macro impact.

Counterpoint

Investors could view the revenue beat and expanding AI client base as a catalyst for upside, betting margin compression is temporary.

Key entities

  • Doximity

    U.S. digital health platform (ticker DOCS).

  • UpToDate

    Clinical reference partner integrated with Doximity.

Related articles

Med

Doximity: 3 Key Takeaways for Long-Term Investors

Doximity updated its full-year revenue guidance to $678M-$683M, citing steady demand and pricing discipline. The company highlights operating efficiency and AI investments as key drivers. According to CFO Matthew Sonefeldt, these factors support continued growth amid technological shifts.

$DOCSMedAI 8/10

Doximity Q2 Earnings Call Highlights

Doximity (DOCS) reported Q2 earnings, raising fiscal 2027 revenue guidance to $678M-$683M. AI Search revenue is expected to ramp gradually. Health system clients grew to 190, including 10 of the top 20 hospitals. Non-GAAP EPS was $0.36, with $713M in cash. Management discussed AI monetization and adoption challenges.

$DOCSMedAI 8/10

Doximity Earnings Call Highlights AI Growth and Guidance

Doximity (DOCS) reported Q2 revenue of $175M (+4% YoY), beating expectations. Adjusted EBITDA was $89M (51% margin), exceeding guidance. AI initiatives drove growth, with expanded health-system adoption and improved AI economics. Revenue guidance raised to $678M-$683M for 2027. Challenges include modest growth, margin pressure, and AI-search return uncertainty.

$DOCSHighAI 8/10

Doximity earnings analysis: questions answered and next catalysts

Doximity Inc (DOCS) reported FQ2 2027 earnings with revenue of $174.5M, beating estimates, but profitability declined. EPS was $0.36 vs. $0.35 estimated. Adjusted EBITDA margin fell to 51% from 60% YoY. The stock is trading at $31.87, down 3.95%. AI spending grew significantly, and management raised FY2027 revenue guidance to $678M–$683M. Legal and growth concerns remain.